Soleus Capital Management’s Travere Therapeutics TVTX Stock Holding History

Soleus Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-546,000	Closed	-$16.2M	–	109
2026 Q1	$16.2M	Buy	+546,000	New	+$16.3M	0.66%	40
2023 Q3	–	Sell	-21,600	Closed	-$332K	–	113
2023 Q2	$332K	Sell	21,600 -213,000	-91%	-$3.87M	0.04%	99
2023 Q1	$5.28M	Buy	+234,600	New	+$4.99M	0.55%	49
2021 Q4	–	Sell	-210,815	Closed	-$5.11M	–	87
2021 Q3	$5.11M	Buy	+210,815	New	+$3.87M	0.8%	37

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Soleus Capital Management's TVTX Position: Q2 2026 in Review

Soleus Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 546,000 shares — an estimated $16.2M sold.

Soleus Capital Management first reported a position in TVTX in Q3 2021 and held it in 4 quarters. The position peaked at $16.2M in Q1 2026. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Soleus Capital Management reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
Soleus Capital Management sold 546,000 Travere Therapeutics shares in Q2 2026, an estimated $16.2M.
Soleus Capital Management first reported a position in Travere Therapeutics in Q3 2021 and held it in 4 quarters.
Soleus Capital Management's Travere Therapeutics position peaked at $16.2M in Q1 2026.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.